Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-03-10

Study Completion Date

2025-11-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will be conducted to address the lack of concrete data on the impact of pharmaceutical intervention on short-term patient satisfaction and quality of life (QoL) in patients with Hidradenitis Suppurativa (HS) in real-world settings, especially in the Gulf Region.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06046729

Hidradenitis Suppurativa

ACTIVE_NOT_RECRUITING PHASE2

A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

NCT03569371

Hidradenitis Suppurativa

COMPLETED PHASE2

Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03487276

Hidradenitis Suppurativa (HS)

COMPLETED PHASE2

Anifrolumab for Hidradenitis Suppurativa

NCT06374212

Hidradenitis Suppurativa Acne Inversa Hidradenitis

ACTIVE_NOT_RECRUITING PHASE2

Etanercept in Hidradenitis Suppurativa

NCT00329823

Hidradenitis Suppurativa

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 24-week longitudinal single-arm prospective study based on data collected from EMRs along with patient-reported outcomes questionnaires (TSQM and DLQI) to evaluate patient-reported satisfaction and early quality of life experiences among HS patients who are newly initiated on Secukinumab. We will be using questionnaires at baseline and at week 24 to report on pre-defined outcomes in a representative HS population across the United Arab Emirates. The data will be collected using an electronic Case Report Form (eCRF) from both data sources (Electronic Medical Report and Questionnaires).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hidradenitis Suppurativa

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Secukinumab

Patients who are newly initiated on treatment with Secukinumab

Secukinumab

Intervention Type OTHER

This is an observational study. There is no treatment allocation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Secukinumab

This is an observational study. There is no treatment allocation.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with a confirmed diagnosis of active moderate to severe HS (Hurley Score 2-3)
* Male or Female adult patients ≥ 18 years of age at the time of data collection
* Patient newly initiated on Secukinumab (first dose to coincide within 1 month of the signature of the informed consent)
* Patients with a diagnosis of HS who are currently using antibiotics/ have undergone surgery or not as part of their routine clinical management are eligible for inclusion.
* Patients with a diagnosis of HS who have a history of previous treatment with Adalimumab or any other anti-TNF agent as part of their routine clinical management or biologic naïve are eligible for inclusion.
* Agreed to sign an informed consent to be able to fill in the questionnaires.

* Patient's refusal to be included in the study or refusal to sign the informed consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No